Gilead stock falls after disappointing lung cancer study results

Gilead stock falls after disappointing lung cancer study results


Sopa Images | Lightrocket | Getty Images

Shares of Gilead fell more than 9% on Monday after a key drug from the company did not significantly extend the lives of patients with a certain lung cancer in a late-stage trial.

The results are a blow to Gilead, which is working to become a power player in the cancer space. The treatment, Trodelvy, is one of Gilead’s best-selling cancer drugs, contributing roughly a third of its $769 million in oncology sales during the third quarter.

The phase-three study is part of an effort to expand the use of Trodelvy, which is already approved to treat some types of breast and bladder cancers.

Patients with advanced or metastatic non-small cell lung cancer who took Trodelvy lived longer than those who got chemotherapy alone, according to Gilead. But those results did not meet the trial’s bar for success. 

The drugmaker said it will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug.

Trodelvy belongs to a class of widely sought-out treatments called antibody-drug conjugates, or ADCs, which deliver a cancer-killing therapy to specifically target and kill cancer cells and minimize damage to healthy ones. Standard chemotherapy is less selective – it can affect both cancer cells and healthy cells.

ADCs are one of the hottest areas of the pharmaceutical industry, as large drugmakers ink deals to acquire or co-develop them.

Jefferies analyst Michael Yee said Gilead’s trial results are not “totally surprising” to the firm because data from early studies was mixed and data for competing drugs was “lackluster”. 

Yee added that the trial results could “dent” investor confidence about whether Gilead will have significant sales in oncology.



Source

UnitedHealth says it is cooperating with DOJ investigation into Medicare billing practices
Health

UnitedHealth says it is cooperating with DOJ investigation into Medicare billing practices

The UnitedHealth logo on a laptop arranged in New York, US, on Friday, July 7, 2023. Gabby Jones | Bloomberg | Getty Images UnitedHealth Group revealed Thursday it is facing a Justice Department investigation over its Medicare billing practices, adding to a string of setbacks for a company that owns the nation’s largest and most […]

Read More
Healthy Returns: Researchers move closer to a universal cancer vaccine
Health

Healthy Returns: Researchers move closer to a universal cancer vaccine

Wildpixel | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A universal cancer vaccine – what once seemed like a pipe dream – may be inching closer to becoming reality.  On […]

Read More
U.S. to remove mercury preservative from flu shots following RFK Jr. vaccine panel vote 
Health

U.S. to remove mercury preservative from flu shots following RFK Jr. vaccine panel vote 

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., speaks with Agriculture Secretary Brooke Rollins and Senator Roger Marshall (R-KS) ahead of a roundtable event as part of the “Make America Healthy Again” (MAHA) agenda, on Capitol Hill in Washington, D.C., U.S., July 15, 2025. Ken Cedeno | Reuters The Department of Health […]

Read More